Summary. Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed.

Collaboration combines Novo Nordisk’ s scientific leadership in obesity and cardiometabolic diseases with Septerna’ s expertise in G protein-coupled receptor drug discovery Goal is to develop ...

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...

On May 14, 2025, Septerna and Novo Nordisk announced a global collaboration agreement to discover, develop and commercialize multiple potential oral small molecule medicines for obesity, ...

Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialise oral ...

Novo Nordisk said on Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to competitor Eli Lilly’s efforts to bring a more ...

Since Septerna’s inception in 2019, the company had raised $224.2 million prior to the IPO, most recently a $150 million Series B round last year led by RA Capital Management.That firm holds a 7 ...

On May 14, 2025, Septerna and Novo Nordisk announced a global collaboration agreement to discover, develop and commercialize multiple potential oral small molecule medicines for obesity, ...